Jonathann Kuo, MD

Certifications

MD

Education

BA: Boston University
MD: Boston University
Residency: New York Presbyterian Hospital / Weill Cornell
Fellowship: New York Presbyterian Hospital / Hospital for Special Surgery / Memorial Sloan Kettering Cancer Center

Founder, CEO, & Medical Director, Pain Medicine

Jonathann Kuo, MD is a double Board-Certified Pain Management Specialist and Anesthesiologist. He is the founder of Hudson Health, an innovative healthcare system with four integrated practices: Hudson Medical for interventional regenerative pain management, Hudson Wellness for preventative wellness, Hudson Mind for interventional mental health, and Hudson Life for functional and longevity medicine.
Since opening Hudson in 2010, Dr. Kuo and his group has treated over 30,000 patients. His dedication to patient care is matched by his steadfast contributions to clinical research. Having collaborated with renowned doctors and health organizations across the globe, Dr. Kuo has emerged as a prominent thought leader across the interventional pain management and orthobiologics fields.
In his spare time, Dr. Kuo is an accomplished artist who has exhibited at several galleries and displays many of his works across Hudson Health’s TriBeCa and West Village practices. He also enjoys biohacking, cycling, travel gastronomy, and spending time with his growing family.
Dr. Kuo graduated from the prestigious 7 year accelerated BA/MD program at Boston University. He then completed his training at one of New York’s top institutions, New York Presbyterian Hospital. He received additional fellowship training in Pain Management at Memorial Sloan Kettering Hospital and the Hospital for Special Surgery.
Hudson Health’s robust Regenerative Medicine practice has performed over 2000 cases to date with proprietary methods of extracting the highest concentrations of biologics using a proprietary and flexible lab platform. Hudson Medical is also the first practice in the US to publish safety data on the use of exosomes in spinal applications, and Dr. Kuo is committed to continually spearheading research in this field.

With a track record of over 30,000 spinal and joint procedures, Dr. Kuo is a highly skilled and seasoned interventionist. His expertise extends to the precise injection of various body parts, including joints, tendons, cartilage, nerves, and intervertebral discs, all guided by X-ray and ultrasound imaging. The integration of regenerative medicine products, like exosomes, concentrated platelet-rich plasma, and peptides has ushered in a groundbreaking era in regenerative medicine. This innovative approach empowers patients to stimulate their body's natural healing processes without the necessity for surgical interventions.

Dr. Kuo actively contributes to clinical research that evaluates the newest biologics and their applications in degenerative spinal and joint and systemic inflammatory conditions. He has traveled extensively to leading laboratories to collaborate with global thought leaders in the regenerative field.
Dr. Kuo has co-authored numerous publications on the use of NAD+, exosomes as potential Long COVID-19 treatments, and the efficacy of Dual Sympathetic Blocks in treating anxiety disorders. He is currently involved in three clinical research projects.

More about Dr. Kuo

Languages

English, Chinese (Mandarin), Chinese (Cantonese), Taiwanese

Hospital affiliation

North Shore / Long Island Jewish Hospital, Mt. Sinai / Beth Israel Medical Center
Rationale for NAD+ Metabalome Disruption as a Pathogenic Mechanism of Post-Acute COVID 19 Syndrome https://pubmed.ncbi.nlm.nih.gov/35769168/

Research

Areas of Interest

Dr. Kuo’s research interests include Regenerative Medicine using Bone Marrow Concentrate which contains stem cells, and Platelet-rich plasma (PRP).
Dr. Kuo’s research interests include Regenerative Medicine using Bone Marrow Concentrate which contains stem cells, and Platelet-rich plasma (PRP).

Clinical Trials

fMRI evaluation of the effect of Stellate Ganglion Blocks for PTSD, in conjunction with NYU Langone and the Stella Center

Clinical Trial

Thought Leadership